AIVITA Biomedical Completes Treatment of Patients in Phase 2 Clinical Trial of Glioblastoma Immunotherapy

About the Author

user

Related Posts

AIVITA Biomedical CEO Hans Keirstead Receives 2021 Global Humanitarian Award

AIVITA Biomedical Completes Phase 1 Study of Personalized COVID-19 Vaccine Candidate, AV-COVID-19

AIVITA Biomedical Closes $25 Million Financing Round

AIVITA Biomedical’s Phase 2 Glioblastoma Trial Shows Improved Progression Free Survival

More From This Category

AIVITA Biomedical CEO Hans Keirstead Receives 2021 Global Humanitarian Award

AIVITA Biomedical Completes Phase 1 Study of Personalized COVID-19 Vaccine Candidate, AV-COVID-19

AIVITA Biomedical Closes $25 Million Financing Round

AIVITA Biomedical’s Phase 2 Glioblastoma Trial Shows Improved Progression Free Survival